[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Manchester University NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":390},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,67,93,115,133,163,190,217,238,259,284,313,339,359],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100627584","the-practicality-and-utility-of-measured-vs-estimated-gfr-in-adckd-100627584",false,"NCT07450534","The Practicality and Utility of Measured vs Estimated GFR in adCKD","The Practicality & Utility of Estimated vs Measured Renal Function in Advanced Kidney Disease, Whether Treated With Dialysis or Not: Can Better Techniques be Used to Predict the Onset of the Uraemic Syndrome and Guide Dialysis Requirements","Inclusion Criteria:\n\n* Adults (18 year s or older)\n* Able to give informed consent\n* Progressive chronic kidney disease predicted to start renal replacement therapy in the next 6 months OR established on dialysis (either haemodialysis or peritoneal) with residual renal function (Urine output \\>100ml\u002Fday)\n\nExclusion Criteria:\n\n* Under 18 years\n* Known allergy to iodinated contrast media\n* Unable to perform fingerprick blood testing\n* Unable to comply with urine collection\n* Unable or unwilling to give informed consent in English\n* Acute kidney injury expected to recover renal function\n* Pre-dialysis and planned renal transplant within 1 month\n* Pregnant or breast feeding\n* Significant fluid overload (significant peripheral oedema or ascites AND \\>10kg above estimated dry weight)","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess if new ways of measuring kidney function can better predict when individuals will become symptomatic due to kidney failure, and whether residual kidney function can be accurately measured in those already on dialysis.\n\nThe main questions the study is trying to answer is whether measuring kidney function by clearance of iohexol is comparable to the current standard of care methods.\n\nIn addition to routine care, participants will:\n\n* undergo a brief clinical assessment\n* be given an injection of iohexol and asked to perform 4 finger prick blood tests over 24 hours, recording the time of each sample. Samples will be returned in person or posted back\n* be asked to complete a questionnaire on their experience",[24,25],"Chronic Kidney Disease (Stages 4 and 5)","Chronic Kidney Disease 5D",[27,28,29],"mGFR","iohexol","Residual Kidney Function","NOT_YET_RECRUITING","2026-02-27",{"date":33,"type":34},"2026-03-04","ACTUAL",{"date":36,"type":20},"2026-02",{"date":38,"type":20},"2027-02",{"name":40,"class":41},"Manchester University NHS Foundation Trust","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100413654","integrated-diagnostics-for-early-diagnosis-of-liver-disease-100413654","NCT04666402","Integrated Diagnostics for Early Diagnosis of Liver Disease","ID LIVER","Inclusion Criteria:\n\n* All patients referred to Community Liver Assessment Clinic.\n* Male or female \\> 18 years of age.\n* Females will be non-pregnant and non-lactating.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnancy\u002Fbreast-feeding. Women of childbearing potential (not \\>2 years post- menopausal and\u002For not surgically sterilised) must have a negative blood serum pregnancy test.\n* Isolated bilirubinaemia.\n* Known pre-existing liver disease.\n* Acutely unwell.\n* Suspected malignancy.",{"count":51,"type":20},1200,"This is an observational study that will explore the hypothesis that by combining data from patients with liver disease with novel blood biomarkers, single nucleotide polymorphism (SNP) analysis and faecal microbiome analysis. The Investigators will improve diagnosis of liver fibrosis compared to the current available diagnostic tools.",[54,55,56,57],"Non-Alcoholic Fatty Liver Disease","Non-alcoholic Steatohepatitis","Alcoholic Liver Disease","Liver Fibroses","RECRUITING","2026-02-05",{"date":61,"type":34},"2026-02-09",{"date":63,"type":34},"2020-10-21",{"date":65,"type":20},"2027-03-31",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100616785","barriers-and-enablers-to-accessing-medical-care-for-urinary-incontinence-and-prolapse-in-global-majority-women-100616785","NCT07310121","Barriers and Enablers to Accessing Medical Care for Urinary Incontinence and Prolapse in GLobal Majority Women","BEAM UP & GLOW","Women who have been referred to MFT for the specified condition.\n\nInclusion Criteria:\n\n* To be willing and able to give informed consent\n* To have been born female and to currently identify as female\n* To be over the age of 18 years\n* To have accessed medical care for urinary incontinence or pelvic organ prolapse\n* To be from an ethnic minority\u002F global majority background\n* To be able to speak and understand English\n\nExclusion Criteria:\n\n\\-\n\nWomen attending select community centres in Greater Manchester area.\n\nInclusion Criteria:\n\n* To be willing and able to give informed consent\n* To have been born female and to currently identify as a woman\n* To be over the age of 18 years\n* To be from an ethnic minority\u002F global majority background\n* To be able to speak and understand either English, or a language which the community group translator can communicate in\n\nExclusion Criteria:\n\n\\-",true,"FEMALE",{"count":77,"type":20},160,"This project aims to explore barriers to treatment seeking for symptoms of prolapse and urinary incontinence in women from ethnic minority\u002Fglobal majority background.\n\nThis study consists of three components, each with different methodological approaches:\n\n1. Collecting objective data using validated questionnaires Prolapse and Incontinence Knowledge Questionnaire (PIKQ), Female Genital Self-Image Scale (FGSIS-4) and prevalence and severity of urinary incontinence and pelvic organ prolapse (ICIQ-UI Short Form and ICIQ-VS), age, level of education, level of deprivation (according to postcode), faith, first or preferred language spoken, sexual orientation and employment status to explore whether these are associated with barriers to treatment seeking as measured by the Barriers to Incontinence Care Seeking Questionnaire (BICS-Q) and to estimate the prevalence of urinary incontinence and prolapse in a community group of women from an ethnic minority\u002Fglobal majority background\n2. Collecting qualitative data via semi-structured interviews with women from an ethnic minority\u002Fglobal majority background who have sought treatment for urinary incontinence or pelvic organ prolapse to explore barriers they may have experienced and how these were overcome and collecting qualitative data via focus group discussions with women from an ethnic minority\u002Fglobal majority background who attend women's community groups\n3. Zine making as a research approach is a creative, participatory method that uses the process of creating zines (small, self-published, often handmade booklets) to generate, explore, and share knowledge . Zine making blends arts-based research and participatory action research and is particularly suited for working with seldom heard communities or exploring stigmatised conditions because it gives participants creative control over how their experiences are communicated, which can be empowering, especially for individuals who are under or misrepresented in mainstream narratives . Zine making is also more accessible for individuals who do not speak English as their first or preferred language, or, have other communication barriers .",[80],"Pelvic Prolapse Conditions",[82,83,84],"Pelvic organ prolapse","Pelvic floor dysfunction","Urinary incontinence","2025-12-15",{"date":87,"type":34},"2025-12-30",{"date":89,"type":20},"2025-12",{"date":91,"type":20},"2026-11-30",{"name":40,"class":41},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":42},"100512669","detecting-early-heart-failure-in-greater-manchester-100512669","NCT05955456","Detecting EARLY Heart Failure in Greater Manchester","Detecting EARLY Heart Failure in Greater Manchester (EARLY-HF)","EARLY-HF","Inclusion Criteria:\n\n* Written informed consent\n* Aged 50 and over\n* Two or more of the following conditions: type 2 diabetes, chronic obstructive pulmonary disease, ischaemic heart disease, atrial fibrillation, hypertension, chronic kidney disease stage 3, body mass index ≥ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Established diagnosis of one or more of the following: heart failure, cardiomyopathy, moderate or severe valvular heart disease, congenital heart disease, heart transplant, idiopathic, heritable or drug-induced pulmonary arterial hypertension, any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his\u002Fher participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.\n* Contraindication to cardiovascular magnetic resonance (CMR) scanning, including pacemaker, defibrillator, intraocular metal, intracranial aneurysm clips, severe claustrophobia, estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m2, previous severe allergic reaction or anaphylaxis to gadolinium-based contrast agent, pregnancy or breastfeeding.","50 Years",{"count":103,"type":20},600,"Heart failure represents a growing public health problem within the UK and particularly within the North West of England. A major challenge is that heart failure is currently diagnosed too late.\n\nThe researchers have previously developed a risk calculator that accurately identifies individuals at risk of heart failure admission or death before they have developed heart failure.\n\nMost risk calculators are never implemented into clinical practice. The researchers will l perform a pilot study to evaluate the risk calculator within primary care in Greater Manchester.",[106],"Heart Failure","2025-09-26",{"date":109,"type":34},"2025-10-01",{"date":111,"type":34},"2023-10-09",{"date":113,"type":20},"2030-09-01",{"name":40,"class":41},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100468707","characteristics-phenotypes-and-traits-of-heart-failure-with-preserved-ejection-fraction-traits-hfpef-100468707","NCT05383287","Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)","TRAITS-HFpEF","Inclusion Criteria:\n\n* Patients attending the HFpEF clinic at MFT.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Imprisonment\n* Inability to provide full written or verbal informed consent in English",{"count":123,"type":20},1250,"Heart failure with preserved ejection fraction (HFpEF), a certain type of heart failure, occurs when the heart doesn't pump blood around the body properly. It can cause breathlessness, tiredness, and swollen feet or ankles. It is not clear why people develop HFpEF and treatment options are very limited.\n\nTRAITS-HFpEF is a study that aims to understand why people develop HFpEF, identify new tests and treatments, and gain information on the life expectancy of people living with this condition. It will do this by routinely collecting information on people attending a specialised outpatient HFpEF clinic.",[126],"Heart Failure With Preserved Ejection Fraction (HFpEF)",{"date":109,"type":34},{"date":129,"type":34},"2022-08-12",{"date":131,"type":20},"2029-10",{"name":40,"class":41},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":142,"phases":143,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":42},"100513871","real-world-elecsys-gaad-implementation-and-validation-to-improve-surveillance-and-early-detection-of-hcc-100513871","NCT05971108","Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC","Real-world Elecsys® GAAD Algorithm Implementation and Validation to Improve Surveillance and Early Detection of Hepatocellular Carcinoma","REVISE-HCC","Inclusion Criteria:\n\n• Patients with known liver cirrhosis referred into or already under hepatocellular carcinoma surveillance\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreast-feeding.\n* Patients who do not have liver cirrhosis\n* Patients who already have hepatocellular carcinoma\n* Any patient who is unable to understand, retain and weigh information to make an informed decision, will be excluded from the study. The investigators will use every opportunity, including tele-interpretation services to minimise this from happening.",{"count":103,"type":20},"INTERVENTIONAL",[144],"NA","Patients with liver cirrhosis are at high risk of developing hepatocellular carcinoma (HCC) which implies significant mortality. At present current surveillance methods detect hepatocellular carcinomas at a late stage resulting in few treatment options for patients and, in the majority of cases, premature death.\n\nThe goal of this study is to implement Elecsys® GAAD in real-world hepatocellular carcinoma surveillance for those with liver cirrhosis.\n\nThe main questions it aims to answer are:\n\n* Does the introduction of the Elecsys® GAAD algorithm to the surveillance pathway increase early detection of HCC?\n* Does the introduction of the Elecsys® GAAD algorithm to the surveillance pathway reduce false positive tests and unnecessary confirmatory investigations?\n* Does the new surveillance pathway improve adherence?\n\nResearchers will compare Elecsys® GAAD with standard of care tests to see if it results in earlier detection of hepatocellular carcinoma and will explore potential improvements to the surveillance pathway.",[147,148],"Liver Cirrhosis","Hepatocellular Carcinoma",[150,151,152,153,154],"GAAD","hepatocellular carcinoma","cirrhosis","health inequalities","surveillance","2025-09-23",{"date":157,"type":34},"2025-09-24",{"date":159,"type":34},"2024-01-08",{"date":161,"type":20},"2030-07-31",{"name":40,"class":41},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":173,"conditions":174,"keywords":181,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100595224","the-accredit-2-study-100595224","NCT07029672","The AcCREDiT 2 Study","Acute Respiratory Infections and Chronic Respiratory Disease Exacerbation Characterisation and Personalised Treatment Platform Study 2","ACCREDIT2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically suspected acute respiratory infection or exacerbation of chronic respiratory disease\n* Availability of respiratory tract sample\n\n  1. Spontaneously breathing patients are able to produce a sputum sample\n  2. Mechanically ventilated patients in intensive care are due to have an Bronchoalveolar lavage or non-directed bronchial lavage for a clinical indication\n* Due to receive either:\n\n  1. an anti-infective agent (e.g. antibiotic, antiviral or antifungal) OR\n  2. a systemic anti-inflammatory agent (e.g. corticosteroid)\n* Valid informed consent, assent or enrolment through deferred consent\n* Re-enrolment will be allowed if presenting for a separate acute event\n\nExclusion Criteria:\n\n* Alternate respiratory cause of presentation in the opinion of the treating physician (e.g. pulmonary embolism, heart failure, etc.)\n* High clinical likelihood of infection with a Hazard Group 3 pathogen (e.g. tuberculosis, anthrax, plague)",{"count":172,"type":20},120,"The ACCREDIT study - Acute respiratory infections and chronic respiratory disease exacerbations characterisation and personalised treatment platform study 2 (AcCREDiT 2).\n\nPatients with respiratory infections (such as pneumonia) or exacerbations of chronic respiratory conditions (such as emphysema) often require hospital admission. Infections or exacerbation are commonly caused by bacteria, viruses or fungi. In at least a quarter of patients no infectious cause of the exacerbation is found. Depending on the cause of the respiratory infections or exacerbations of chronic respiratory condition patients require prompt treatment with anti-infective drugs (antibiotics, anti-fungal or antiviral drugs) or anti-inflammatory drugs such as corticosteroids.\n\nPatients with respiratory infection or exacerbations of chronic respiratory conditions develop symptoms such as cough, sometimes with sputum, fever or breathlessness. These symptoms can be similar across several conditions, many of which are not due to infection (for example heart failure or blood clots in the lungs). When assessing patients with respiratory symptoms, clinicians face the challenge of limited information in the early stages of care as it takes three days to identify infectious organisms in the laboratory. Even when an infection is strongly suspected, distinguishing bacterial from viral or fungal infections on clinical grounds alone is difficult. This uncertainty often leads clinicians to prescribe a number of treatments, including antibiotics, before a clear diagnosis is made. Timely treatment is crucial for success and improved patient outcomes, especially for critically ill patients admitted to the intensive care unit (ICU). However, antibiotics may cause side effects, such as sickness and diarrhoea, and overuse of antibiotics leads to antibiotic resistance, making antibiotics less effective when they are really needed. Giving antibiotics to patients with an infection or exacerbation and avoiding antibiotics in patients without an infection requires rapid diagnostic tests. Furthermore, giving antibiotics prior to taking samples to diagnose infection can affect the sample being tested making it more likely to not give a useful result. For a diagnostic test for infection to be most useful it needs to be collected before an antibiotic is given - this is true for both clinical tests and those research tests which are clinical tests in development.\n\nModern technologies allow testing for an infection in hours rather than days. In order to understand how effective these technologies are, samples need to be taken from patients before they start treatment. In routine NHS care samples to test for infection should be taken before treatment has been started. However, in research studies samples are often taken up to a day after treatment has started which affects how effective the test is at finding infection. The forerunner to this study, called AcCREDiT, proposed investigating very rapid ways of identifying individuals with respiratory infection and exacerbation. However, the study team encountered challenges during the informed consent process, particularly with acutely unwell patients. Therefore, the AcCREDiT-2 was designed in collaboration with patients and public contributors to look at the feasibility of a modified informed consent process: verbal consent, assent for individuals with capacity to consent for themselves, and deferred consent.\n\nAcCREDiT-2 will be an observational study, meaning that no treatment will be changed, and no experimental drugs or tests used to influence the clinical care of participants. AcCREDiT-2 will also be a 'feasibility study', which is a smaller study designed to see what works well before embarking on a larger project. During the study the investigators will collect clinical information and samples, such as blood, sputum and stool, from patients who come to hospital with a presumed respiratory infection or exacerbation of their chronic respiratory condition. The investigators will compare new diagnostic tests to traditional laboratory tests to understand their relative advantages and disadvantages for patient care.\n\nThis is a 'feasibility' study, a small study ran first to make sure things work properly before expanding to a much larger study.",[175,176,177,178,179,180],"Chronic Respiratory Conditions","COPD","Pneumonia","Bacterial Infections","Viral Infections","Respiratory Exacerbation",[182],"ACCREDIT","2025-07-01",{"date":185,"type":34},"2025-07-04",{"date":183,"type":20},{"date":188,"type":20},"2026-04",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100590808","glucose-levels-in-acute-pancreatitis-and-the-impact-of-insulin-depletion-and-bacterial-endotoxaemia-100590808","NCT06972238","Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia","A Prospective Observational Study of Acute Pancreatitis Severity and the Association of Glucose Time in Range and Stress Hyperglycaemia, Plasma Insulin Depletion and Bacterial Endotoxaemia","GLIDE","Inclusion Criteria:\n\n1. Age 18 years or over\n2. Admission diagnosis of acute pancreatitis (based on Revised Atlanta Criteria)\n3. Ability to provide informed consent in English\n\nExclusion Criteria:\n\n1. Known diabetes mellitus\n2. Use of insulin therapy before admission\n3. Pregnancy\n4. Contraindications to CGM (e.g., allergy to device adhesive)",{"count":199,"type":20},30,"There are currently no early predictive biomarkers for severity of acute pancreatitis (AP) that would allow stratification of patients for potential early interventional therapies. Hyperglycaemia is frequently observed to accompany and contribute to severe AP. However, the underlying mechanism is multifactorial, including in the acute phase of injury, where elevated adrenaline, cortisol and glucagon and inflammatory cytokine-induced insulin resistance all contribute to hyperglycaemia. The investigators propose that the extent of collateral injury of pancreatic β-cells and consequent loss of insulin secretion during the course of acute pancreatitis (AP) underlies disease severity. The investigators will measure plasma C-peptide (as a reliable readout of endogenous insulin), with moment-to-moment glucose monitoring (using subcutaneous continuous glucose monitoring devices), and bacterial endotoxin (lipopolysaccharide (LPS) in a prospective cohort of 30 severe AP patient blood samples taken every 5 days for up to 5 weeks of hospitalization.",[202,203],"Pancreatitis, Acute","Hyperglycaemia",[205,203,206,207,208],"Pancreatitis","inflammation","clinical severity","beta-cell","2025-05-16",{"date":211,"type":34},"2025-05-21",{"date":213,"type":20},"2025-12-01",{"date":215,"type":20},"2026-08-30",{"name":40,"class":41},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":142,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":42},"100359425","the-impact-of-abdominal-wall-closure-technique-on-incidence-of-incisional-hernia-in-kidney-transplantation-100359425","NCT03959904","The Impact of Abdominal Wall Closure Technique on Incidence of Incisional Hernia in Kidney Transplantation","Inclusion Criteria:\n\n* End-stage renal failure patients\n* Aged 18-70yrs\n* First transplants or second transplants\n* Ability to adequately understand English and consent for study\n* BMI\\\u003C35 kg\u002Fm2)\n* Living donor nephrectomy patients Exclusion Criteria\n* Outside age range,\n* Previous transplants which have left a scar in the ilia fossa","70 Years",{"count":225,"type":20},50,[144],"STUDY SUMMARY Incisional hernias, or swellings of the abdominal scar after surgery, remain problematic especially after transplant surgery. This is because they can cause complications, including trapping of bowel or the transplant. This can cause life threatening emergencies but is at the very least unsightly and uncomfortable for the patient. Transplant patients are especially likely to develop hernias because of the diseases causing the renal failure and the drugs that they take to dampen the immune system. There is evidence from other surgery that the stitching methods that are used to close the wounds might decrease the risk of surgical hernias. This is achieved by placing smaller and more numerous sutures (stitches) in the wound to increase the strength of the repair. However, this has never been tested formally in transplant where it may provide significant benefit. We intend to do some initial investigation of whether using the smaller stitches may provide benefit over more traditional methods that are currently being used. We will look at early complications after surgery but also the rate of hernia formation later. We hope to improve outcomes and reduce complications for our transplant patients by doing this. In addition we will collect blood and tissue samples from both live kidney donors and the recipients to microscopically analyse their collagen to identify potential factors which may indicate risk of hernia formation.",[229],"Surgery--Complications","2025-05-08",{"date":232,"type":34},"2025-05-09",{"date":234,"type":34},"2020-03-10",{"date":236,"type":20},"2026-06-30",{"name":40,"class":41},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100473203","uk-heart-failure-with-preserved-ejection-fraction-100473203","NCT05441839","UK Heart Failure With Preserved Ejection Fraction","UK Heart Failure With Preserved Ejection Fraction Registry","UK HFpEF","Inclusion Criteria:\n\n1. Written informed consent\n2. Diagnosis of HFpEF by a cardiologist with HF expertise, or a primary care physician with HF expertise, or a heart failure nurse\n3. Natriuretic peptide levels measured\n\nExclusion Criteria:\n\n1. LV EF \\\u003C 40% (at screening or any previous measurement)\n2. Known infiltrative cardiomyopathy (e.g., amyloid, sarcoid, lymphoma, endomyocardial fibrosis)\n3. Known active myocarditis, constrictive pericarditis, or cardiac tamponade\n4. Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy\n5. Known arrhythmogenic right ventricular cardiomyopathy\n6. Known severe primary valvular heart disease\n7. Known idiopathic, heritable or drug-induced pulmonary arterial hypertension\n8. Heart transplantation or ventricular assist device\n9. Complex congenital heart disease",{"count":247,"type":20},10000,"Heart failure occurs when the heart is no longer able to pump blood around the body properly. It can cause breathlessness, swollen feet and ankles, and tiredness. In about half of patients with heart failure, one measure of the heart's pumping function, called the 'ejection fraction', is normal. This type of heart failure is called heart failure with preserved ejection fraction, or HFpEF.\n\nHFpEF remains poorly understood. It is not clear why some people develop HFpEF, or what determines the severity of the condition. Treatment options may be limited.\n\nUK HFpEF is a study that aims to gain a better understanding of why people develop HFpEF, develop better tests to diagnosis it, identify and test new treatments, and follow the health of the people taking part over many years.",[126],"2025-05-01",{"date":252,"type":34},"2025-05-06",{"date":254,"type":34},"2022-10-07",{"date":256,"type":20},"2037-06-01",{"name":40,"class":41},26,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":142,"phases":267,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":42},"100489444","phase-2-interferon-gamma-as-adjunctive-therapy-in-chronic-pulmonary-aspergillosis-a-randomised-feasibility-study-100489444","NCT05653193","Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study","INCAS","Inclusion Criteria:\n\n* Diagnosis of CPA\n* Started antifungal treatment for CPA within the last 8 weeks and received no antifungals for CPA in the 8 weeks prior\n* Chest CT scan available within the 6 months prior to enrolment\n* Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception\n\nExclusion Criteria:\n\n* Moderate to severe liver dysfunction (Child-Pugh Class B or C)\n* Renal failure (eGFR \\\u003C30 mL\u002Fmin)\n* Clinically diagnosed active depression\n* Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease\n* Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response to treatment\n* Use of any interferon formulation within the preceding six months\n* Active viral hepatitis infection\n* Pregnancy or breastfeeding\n* Immunosuppression (\\>15mg prednisolone\u002Fday for at least four weeks or equivalent) within the preceding six months\n* Inability to self-administer subcutaneous medications AND lack of a carer who can administer\n* Participants lacking capacity to consent",{"count":225,"type":20},[268],"PHASE2","This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung disease like Chronic Obstructive Lung Disease (COPD) or previously treated tuberculosis (TB). It causes gradual destruction of lung tissue by slowly enlarging cavities, frequent secondary infections and poor quality of life. Because of its indolent nature and nonspecific x-ray findings, it often remains unrecognised for years. Around 3600 people live with CPA in the United Kingdom. Mortality from CPA may be up to 40% in five years.\n\nTreatment for CPA relies on antifungals for prolonged periods, but only around 60% of patients improve. It is often long-term or lifelong as the response is slow and some patients experience relapses. In addition, only one class of oral antifungal drugs is licensed for CPA, and they are associated with side effects and high cost. Better treatments are needed for CPA. We do not know why many patients do not respond to treatment. Maybe CPA patients have a weakened immune system and are more susceptible to Aspergillus. Our data suggest that CPA patients produce lower amounts of ΙFNγ, a substance that facilitates the immune system's response against Aspergillus. We have also shown that, when given to patients with CPA who have failed to improve on antifungal treatment, interferon-gamma leads to improvement in important patient-centred outcomes like flares of lung disease or hospital admissions. Interferon-gamma is already in use in the National Health Service of the United Kingdom for other indications. Therefore, its use in CPA should be explored. However, CPA is a rare condition and the tolerability of interferon-gamma is not fully established in these patients. To understand whether a large-scale study is feasible in CPA, we first need preliminary data in smaller numbers of patients.\n\nWe are conducting a randomised trial of interferon-gamma in addition to antifungals in CPA. Patients with CPA starting antifungal treatment are eligible. Participants (25 per group) are randomly assigned to interferon-gamma for 12 weeks (in addition to antifungals) or antifungals only. To test whether the treatment works, we will use measurements of the cavities on chest CT scan and scores on a quality-of-life questionnaire. We will assess for tolerability of treatment at intervals similar to clinical practice. Criteria for progression to the large-scale study will be set based on the proportion of patients willing to participate, and on the proportion who complete the treatment. Data collected on those parameters will allow us to determine the number needed for a definite study.\n\nIf the large-scale study confirms our observations that interferon-gamma improves outcomes in CPA, then treatment duration can be shortened and relapses avoided. In addition, interferon-gamma can then be explored in other chronic lung disease.",[271,272],"Chronic Pulmonary Aspergillosis","Aspergillosis",[274,275],"immunotherapy","interferon gamma","2025-02-27",{"date":278,"type":34},"2025-03-03",{"date":280,"type":34},"2024-05-17",{"date":282,"type":20},"2026-12",{"name":40,"class":41},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":42},"100568462","exploring-the-lived-experience-of-young-adults-with-severe-asthma-100568462","NCT06681545","Exploring the Lived Experience of Young Adults With Severe Asthma","An Exploration of the Experiences and Support Needs of Young Adults With Severe and Uncontrolled Asthma","EaSY","Inclusion Criteria:\n\n* A confirmed diagnosis of severe or uncontrolled asthma under the care of the Manchester or Liverpool severe asthma services\n* Participants aged 16-25 years.\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Participants with additional long-term conditions who identify their dominant health concern to be non-asthma related.\n* Focus group only- inability to converse in English","16 Years","25 Years",{"count":295,"type":20},46,"Asthma is a serious long-term lung condition caused by swollen airways that narrow. This causes wheezing, chest tightness, and breathlessness. Most asthma is well-controlled with medication.\n\nHowever, 5-10% of asthmatics have severe asthma where treatment does not control symptoms and up to 67% of asthmatics have uncontrolled asthma, caused by not always taking medication as recommended, lifestyle choices or other health problems worsening their asthma.\n\nIn the UK, asthma affects around 800,000 young adults. This group is at high-risk of having poor asthma control, worse outcomes than other age-groups. This is because young adults need care that differs from other age-groups and current care is not meeting these needs.\n\nThere is little information on the experiences and needs of this group and very few studies exist, exploring how to improve care. This study will explore the experiences and needs of young adults (age16-25) with severe and uncontrolled asthma.\n\nMethods. The investigators will perform two study-arms with young adults with severe\u002Funcontrolled asthma in Manchester and Liverpool severe asthma centres:\n\nStudy-arm 1: Interview participants using photographs chosen by them to help explain their experiences of living with asthma and support that they need.\n\nStudy arm 2: Perform group interviews to understand participants' thoughts around the insights from study-arm 1 combined with their own experiences. To explore and develop ideas on how to improve future care.\n\nAt the end of both study arms, a workshop involving patients and stakeholders involved in delivering care will take place, to identify a joint goal of how to improve care in this cohort and map ways in which to achieve this.\n\nTogether, the study results and workshop will increase our understanding of the experiences and needs of young adults with asthma. Helping us to identify new ways to improve care which can be tested in future research.",[298,299,300],"Asthma","Severe Asthma","Uncontrolled Asthma",[302,303,304],"young people","young adults","young person","2025-02-03",{"date":307,"type":34},"2025-02-05",{"date":309,"type":34},"2024-11-25",{"date":311,"type":20},"2025-10-31",{"name":40,"class":41},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":223,"enrollmentInfo":321,"targetDuration":4,"studyType":142,"phases":323,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":42},"100512348","quantifying-artificial-pancreas-related-changes-in-diabetic-neuropathy-100512348","NCT05951283","Quantifying Artificial Pancreas-related Changes in Diabetic Neuropathy","A Longitudinal, Single Centre Study to Assess the Effects of Artificial Pancreas-related Changes in Diabetic Neuropathy","QUANT-AP","Inclusion Criteria:\n\nType 1 diabetes aged 18-70 who falls into either of these three categories and has the ability to read and comprehend English:\n\nStarting Artificial Pancreas therapy as determined for clinical need Starting insulin pump therapy as determined for clinical need On multiple daily injection therapy for insulin delivery\n\nExclusion Criteria:\n\n* History of ocular disease that may affect the cornea.\n* History of corneal trauma or surgery (NB cataract surgery does not preclude enrolment unless surgery occurred in the 3 months prior to enrolment date)\n* Concurrent ocular disease, infection or inflammation.\n* History of neuropathy due to alcoholism, renal impairment requiring renal replacement therapy, infectious disease (e.g., Lyme disease, HIV\u002FAIDS, hepatitis B), liver failure, B12 deficiency\n* Unable to read and comprehend English",{"count":322,"type":20},102,[144],"A complication of diabetes mellitus is damage to nerves called neuropathy. There are several mechanisms involved that will lead to the development of neuropathy. Neuropathy can lead to foot ulcers, infections and amputations. Patients with neuropathy may also experience pain, which can be difficult to control and the medications are limited by side effects. Despite this there are no approved treatments to reverse the progression of neuropathy and the management of patients is focused on controlling blood glucose and other metabolic factors to prevent neuropathy and its symptoms from getting worse.\n\nPatients with type 1 diabetes are prescribed multiple daily injections (MDI) of insulin to manage their glucose control. However, insulin pump therapy and, more recently, automated insulin delivery (AID) or the Artificial Pancreas can be used as the insulin delivery method for patients with type 1 diabetes mellitus. Manchester Diabetes Centre is the first adult diabetes centre in Europe to pioneer and use a commercially-approved AID in clinical practice.\n\nInsulin pump therapy and AID have the advantage of being able to provide insulin at variable doses, which is closer to the natural process occurring within an individual without diabetes. Both are currently considered to be the most physiological method of insulin delivery and have been shown to improve glycaemic control, quality of life (QOL) and reduce the risk of hypoglycaemia (low blood glucose level). The investigators have previously shown in a small group of people that use of an insulin pump therapy may improve symptoms of painful neuropathy via a more stable glucose profile. The peaks and drops in insulin may make neuropathy worse.\n\nIn this study the investigators aim to investigate the use of insulin pump therapy and AID in their effect on neuropathy. This will be in comparison to a control group of patients on MDI. The investigatorsbwill use a variety of neuropathy measures and symptom questionnaires to assess structural and functional neuropathy status. The investigators hypothesise that those patients receiving the newer technologies will demonstrate an improvement in symptoms and nerve regeneration.\n\nThis finding would have a significant impact for patients as it would provide evidence to suggest that those patients with neuropathy should be put onto an insulin pump or AID to improve neuropathy and its symptoms. As these are treatments that are already available on the NHS to patients satisfying specific criteria this study aims to show benefit in this cohort of patients which can be implemented immediately in clinical practice.",[326,327,328],"Diabetes Complications","Diabetes Mellitus, Type 1","Diabetic Neuropathies",[330],"Diabetes","2023-10-27",{"date":333,"type":34},"2023-10-30",{"date":335,"type":20},"2023-12-01",{"date":337,"type":20},"2026-07-01",{"name":40,"class":41},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":42},"100224113","abnormal-lipids---causes-and-effects-100224113","NCT02195050","Abnormal Lipids - Causes and Effects","Hypertriglyceridaemia: Therapeutic Targets, Genetic Causes, and Associated Neuropathy","Inclusion Criteria:\n\n* Therapeutic target arm\n\n  * Statin treated patients with and without hypertriglyceridemia.\n  * Statin treated patients with type 2 diabetes.\n  * Statin treated patients with CKD stages 4 and 5.\n* Nerve function arm\n\n  •Patients known to have severe hypertriglyceridaemia (defined as triglyceride \\>5.5 mmol\u002Fl) but not known to have diabetes and matched controls.\n* Genetic screening arm\n\n  * Patients with a documented triglyceride level of more than 10 mmol\u002Fl at any time.\n  * Criteria for screening for FH and LAL deficiency include non-obese patients (BMI \\\u003C30) with low HDL-C (\\\u003C1.0 mmol\u002Fl male and \\\u003C1.3 mmol female), high triglycerides \\>1.7 mmol\u002Fl, high total cholesterol \\>6.2 or LDL cholesterol \\>4.7 mmol\u002Fl; patients with raised liver alanine aminotransferase (ALT) (1.5 x above ULN) but no metabolic or viral disease or alcohol excess and patients diagnosed with NAFLD with or without hyperlipidaemia.\n\nExclusion Criteria:\n\n* Pregnant and\u002For breast-feeding women.\n* Significant liver impairment.\n* Patients known to have active malignant disease.\n* Patients treated with medications that could affect lipoprotein metabolism significantly (like atypical antipsychotics, chemotherapy).\n* Untreated hypothyroid and hyperthyroidism (if treated and TFT normal could be recruited).",{"count":347,"type":20},1396,"1. At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations:\n\n   1. Tertiary centre lipid clinic patients with raised TG treated with statins.\n   2. Patients with type 2 diabetes treated with statins.\n   3. Patients with Chronic Kidney disease (CKD) stages 4 and 5 treated with statins.\n2. Despite achieving LDL-C and non-HDL-C targets, a significant number of statin-treated patients have residual cardiovascular risk related to raised hsCRP. The relationship between hsCRP and Lp-PLA2 (markers of inflammation) and LDL particle number measured by apoB100 is stronger than that of measured and calculated LDL and non-HDL. In statin treated patients there will be higher levels of hs-CRP and Lp-PLA2 in patients achieving LDL targets but not apo B targets.\n3. We hypothesise that non-diabetic patients with severe hypertriglyceridaemia (fasting serum triglyceride \\>5.5 mmol\u002Fl) have evidence of greater nerve damage compared with matched controls.\n4. LAL deficiency is underdiagnosed in patients with severe hypertriglyceridaemia, low HDL-C, hyperlipidaemias, non alcoholic fatty liver disease and idiopathic high liver enzymes.",[350],"Hypertriglyceridaemia","2023-05-30",{"date":353,"type":34},"2023-05-31",{"date":355,"type":34},"2014-01-23",{"date":357,"type":20},"2030-12",{"name":40,"class":41},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":74,"sex":16,"minAge":367,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":42},"100222156","paraoxonase-and-hdl-qualities-in-glycaemia-and-inflammation-100222156","NCT02169518","Paraoxonase and HDL Qualities in Glycaemia and Inflammation","Changes in Paraoxonase Activity, HDL Properties, Inflammatory Markers and Corneal Innervation in Post-bariatric Surgery Patients, Type 1 Diabetics With and Without Nephropathy, Type 2 Diabetics, and During an Oral Glucose Tolerance Test.","PON1","Inclusion Criteria:\n\n* Patients with Type 1 diabetes who are not receiving lipid-lowering drugs, omega fatty acid supplements or thiazolidinediones and without clinical and\u002For ECG evidence of CHD.\n\nType 2 diabetic patients who are not receiving omega fatty acid supplements or thiazolidinediones and without clinical and\u002For ECG evidence of CHD.\n\nPatients with impaired fasting glucose undergoing oral glucose tolerance test. Patients scheduled for bariatric surgery. Healthy controls who have no major acute or chronic illness, are not receiving regular medication and not taking omega fatty acid supplements, do not have clinically overt ischaemic heart disease.\n\nSubjects (male and female) aged between 20 and 75. Subjects who have capacity and understanding for informed consent process.\n\nExclusion Criteria:\n\n* Type 1 diabetics using lipid lowering therapy, thiazolidinediones, omega fatty acid supplements. History and\u002For ECG evidence of ST segment changes indicative of CHD.\n\nType 2 diabetics receiving thiazolidinediones, omega fatty acid supplements. History and\u002For ECG evidence of ST segment changes indicative of CHD.\n\nHealthy controls who have any history of CHD, vascular insufficiency, or diabetes. Use of any lipid-lowering drug or omega fatty acid supplements.","20 Years","75 Years",{"count":103,"type":20},"The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics.\n\nInflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese person is a vast source of inflammation. Diabetics have abnormal glucose and cholesterol metabolism which ultimately compromise their bodies' circulatory system and nerve function.\n\nCholesterol plays a vital role in CHD. Low-density lipoprotein (LDL) particles carry cholesterol and deposit it in blood vessel walls which become damaged as a result. When LDL particles undergo changes chemically (called oxidation) or as a result of high circulating blood glucose (called glycation), they become more harmful to the body. High-density lipoprotein (HDL) particles have a protective function in CHD. Not only do they transport cholesterol away from the blood vessels to the liver to be broken down, they have properties against oxidation and inflammation. These properties are related to the activity of an enzyme on HDL called paraoxonase 1(PON1).\n\nSuper-obese patients are increasingly treated by weight-reducing surgery (bariatric surgery). In this study we examine whether weight loss following bariatric surgery results in reduced inflammatory state, improved HDL function (higher PON1 activity), better control of blood glucose and less nerve damage.\n\nWe will study PON1 activity, inflammation and glucose control in patients with type 1 diabetes (with and without kidney damage) and type 2 diabetes. We will also study the effects of rapidly rising blood glucose levels on PON1 and glycated LDL in patients undergoing oral glucose tolerance test.",[372,373],"Diabetes Mellitus","Bariatric Surgery Candidate",[375,376,377,378,379,380,381],"PON1 activity","HDL functionality","LDL oxidation","Diabetes Mellitus Type 1","Obesity","Diabetes Mellitus Type 2","Bariatric Surgery","2023-04-11",{"date":384,"type":34},"2023-04-12",{"date":386,"type":34},"2012-07-05",{"date":388,"type":20},"2030-01-31",{"name":40,"class":41},""]